article thumbnail

Medtronic Announces FDA Approval of Newest-generation Evolut TAVR System for Treatment of Symptomatic Severe Aortic Stenosis

DAIC

milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aortic valve replacement (TAVR) system for the treatment of symptomatic severe aortic stenosis. Circulation.

TAVR 111
article thumbnail

What Are the Implications of Choosing a TAVR-First Strategy in the Lifetime Management of Aortic Stenosis?: A Critical Review of TAVR-Explant- and Redo-TAVR

Circulation: Cardiovascular Interventions

Circulation: Cardiovascular Interventions, Ahead of Print. Some patients with aortic stenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aortic valve replacement (TAVR) as the initial intervention may be appealing to many.

TAVR 73
article thumbnail

Abstract 4141954: Laser Ablation to Prevent Coronary Obstruction and Sustain Coronary Access in redo-TAVR: a Feasibility Study

Circulation

Circulation, Volume 150, Issue Suppl_1 , Page A4141954-A4141954, November 12, 2024. Introduction:Redo-transcatheter aortic valve replacement (TAVR) is a promising treatment for transcatheter aortic valve degeneration, becoming increasingly relevant with an aging population.

TAVR 40
article thumbnail

Feasibility of Coronary Access Following Redo-TAVR for Evolut Failure: A Computed Tomography Simulation Study

Circulation: Cardiovascular Interventions

Circulation: Cardiovascular Interventions, Volume 16, Issue 11 , Page e013238, November 1, 2023. BACKGROUND:Coronary accessibility following redo–transcatheter aortic valve replacement (redo-TAVR) is increasingly important, particularly in younger low-risk patients. Two initial Evolut implant depths were analyzed, 3 and 5 mm.

TAVR 40
article thumbnail

Daily Physical Activity Measured by Wearable Smartwatch for Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the SMART TAVR Study

Circulation: Cardiovascular Quality & Outcomes

Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. CONCLUSIONS:Daily step counts rapidly increased within the first 2 months post-TAVR. Increased physical activity was associated with a lower risk of 1-year mortality or rehospitalization after TAVR for patients with daily step counts below 5000.REGISTRATION:URL:[link]

TAVR 40
article thumbnail

Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

DAIC

Widely recognized for pioneering innovative concepts and techniques in TAVR, Tang has set contemporary standards in the field. His research centers on the comprehensive management of patients post-TAVR, transcatheter mitral and tricuspid valve interventions, and advanced imaging techniques in structural heart disease.

TAVR 105
article thumbnail

Valve-in-Valve TAVR in Patients With Failed Trifecta Bioprosthetic Aortic Valves

Circulation: Cardiovascular Interventions

Circulation: Cardiovascular Interventions, Ahead of Print.